Literature DB >> 30868251

[Rapid progressive glomerulonephritis].

Marion Haubitz1.   

Abstract

The rapid progressive glomerulonephritis is an emergency case. Renal function is rapidly lost within weeks or a few months (rarely within days) due to necrotizing extracapillary proliferative crescentic glomerulonephritis. Early diagnosis and treatment improve prognosis, as the best prognostic marker is creatinine when treatment is initiated. Three classes can be distinguished by immunofluorescence in histology. Firstly, there are no or only few immunoglobulins found (anti-neutrophil cytoplasmic antibody [ANCA]-associated vasculitis). Secondly, there is linear immunofluorescence due to antibodies against the glomerular basement membrane (anti-glomerular basement membrane [GBM] disease or Goodpasture syndrome); and thirdly, there is a granular pattern of immunoglobulin deposition (for example systemic lupus erythematosus [SLE], Schoenlein-Henoch purpura or cryoglobulinaemia). The immunosuppressive repertoire has improved (such as induction therapy in ANCA-associated vasculitis with lower total steroid dose, cyclophosphamide pulses or rituximab). New treatment approaches are on their way and the prognosis regarding life expectancy and renal function has improved. There are still challenging questions to answer like treatment duration and markers of recurrence.

Entities:  

Keywords:  ANCA-associated vasculitis; Goodpasture syndrome; Immunosuppression; Rituximab; Steroids

Mesh:

Substances:

Year:  2019        PMID: 30868251     DOI: 10.1007/s00108-019-0575-x

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  23 in total

Review 1.  Circulating endothelial cells and vasculitis.

Authors:  Marion Haubitz; Alexander Woywodt
Journal:  Intern Med       Date:  2004-08       Impact factor: 1.271

2.  Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

Authors:  John H Stone; Peter A Merkel; Robert Spiera; Philip Seo; Carol A Langford; Gary S Hoffman; Cees G M Kallenberg; E William St Clair; Anthony Turkiewicz; Nadia K Tchao; Lisa Webber; Linna Ding; Lourdes P Sejismundo; Kathleen Mieras; David Weitzenkamp; David Ikle; Vicki Seyfert-Margolis; Mark Mueller; Paul Brunetta; Nancy B Allen; Fernando C Fervenza; Duvuru Geetha; Karina A Keogh; Eugene Y Kissin; Paul A Monach; Tobias Peikert; Coen Stegeman; Steven R Ytterberg; Ulrich Specks
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

3.  Histopathologic classification of ANCA-associated glomerulonephritis.

Authors:  Annelies E Berden; Franco Ferrario; E Christiaan Hagen; David R Jayne; J Charles Jennette; Kensuke Joh; Irmgard Neumann; Laure-Hélène Noël; Charles D Pusey; Rüdiger Waldherr; Jan A Bruijn; Ingeborg M Bajema
Journal:  J Am Soc Nephrol       Date:  2010-07-08       Impact factor: 10.121

4.  [Renal manifestation in ANCA-associated vasculitis].

Authors:  Marion Haubitz
Journal:  Dtsch Med Wochenschr       Date:  2018-01-22       Impact factor: 0.628

5.  Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis.

Authors:  Alexandre Karras; Christian Pagnoux; Marion Haubitz; Kirsten de Groot; Xavier Puechal; Jan Willem Cohen Tervaert; Mårten Segelmark; Loic Guillevin; David Jayne
Journal:  Ann Rheum Dis       Date:  2017-05-25       Impact factor: 19.103

6.  Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study.

Authors:  M Haubitz; S Schellong; U Göbel; H J Schurek; D Schaumann; K M Koch; R Brunkhorst
Journal:  Arthritis Rheum       Date:  1998-10

7.  Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patients.

Authors:  Svjetlana Lovric; Uta Erdbruegger; Philipp Kümpers; Alexander Woywodt; Christian Koenecke; Heiner Wedemeyer; Hermann Haller; Marion Haubitz
Journal:  Nephrol Dial Transplant       Date:  2008-08-06       Impact factor: 5.992

Review 8.  Anti-glomerular basement membrane disease: an update on subgroups, pathogenesis and therapies.

Authors:  Mårten Segelmark; Thomas Hellmark
Journal:  Nephrol Dial Transplant       Date:  2019-11-01       Impact factor: 5.992

9.  Use of rituximab as an induction therapy in anti-glomerular basement-membrane disease.

Authors:  M Heitz; P L Carron; G Clavarino; T Jouve; N Pinel; F Guebre-Egziabher; L Rostaing
Journal:  BMC Nephrol       Date:  2018-09-20       Impact factor: 2.388

10.  Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis.

Authors:  Stephen P McAdoo; Nicholas Medjeral-Thomas; Seerapani Gopaluni; Anisha Tanna; Nicholas Mansfield; Jack Galliford; Megan Griffith; Jeremy Levy; Thomas D Cairns; David Jayne; Alan D Salama; Charles D Pusey
Journal:  Nephrol Dial Transplant       Date:  2019-01-01       Impact factor: 5.992

View more
  2 in total

1.  [Acute on chronic renal failure in a 62-year-old man with ANCA-associated vasculitis].

Authors:  C Schroeder; H Schenk; A Khalifa; J H Braesen; S von Vietinghoff
Journal:  Internist (Berl)       Date:  2019-10       Impact factor: 0.743

Review 2.  Anca-positive vasculitis with full-house nephropathy, an unusual association: a case report and review of literature.

Authors:  Carlos Mauricio Martínez Montalvo; Laura Catalina Gutierrez; Carolina Perez; Harrison Herrera Delgado; Paula Corinna Martinez Barrios
Journal:  J Bras Nefrol       Date:  2022 Apr-Jun
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.